论文部分内容阅读
用法国的ELSA CA125药盒以RIA方定量检测146例患者血清中的肿瘤抗原CA125~(TM)。146例被检者包括卵巢癌患者19例,良性卵巢肿瘤患者42例,其它疾病患者85例。所有被检者都经病理证实。检测结果如下:19例卵巢癌患者中,CA125~(TM)>35U/ml有16例(84.2％),>65U/ml有14例(73.7％);42例良性卵巢肿瘤患者中CA125~(TM)>35U/ml有17例(40.5％),>65U/ml有9例(21.4％);85例其它疾病患者中CA125~(TM)>35U/ml有21例(24.7％),>65U/ml有13例(15.3％)。以65U/ml作为血清CA125~(TM)正常值的上限,检测
The CA125 ~ (TM) tumor antigen in 146 patients was quantitatively assayed by RIA in France ELSA CA125 kit. 146 cases were detected in 19 cases of ovarian cancer patients, 42 cases of benign ovarian tumors, 85 cases of other diseases. All subjects were pathologically confirmed. The detection results were as follows: Among the 19 patients with ovarian cancer, CA125 ~ (TM)> 35U / ml in 16 patients (84.2%) and> 65U / ml in 14 patients (73.7%); 42 patients with benign ovarian tumors CA125 ~ TM> 35U / ml in 17 cases (40.5%) and> 65U / ml in 9 cases (21.4%). There were 21 cases (24.7%) of CA125T> 35U / Thirteen patients (15.3%) had 65U / ml. To 65U / ml as the normal serum CA125 ~ (TM) the upper limit of detection